Canada is set to be the first country to give citizens the option for a vegetarian coronavirus shot. The world’s first plant-derived Covid vaccine, Covifenz, was cleared for use in
Posts From editor
Public health authorities and vaccine makers have debated whether an omicron-specific booster or additional shots will be necessary to protect those already immunized as the COVID-19 pandemic continues. While data
![Brexit – Implications For the Pharma Industry in Ireland](http://www.biopharmabusiness.com/wp-content/uploads/2017/12/McGeePharmaBrexitIrelandResized-505x306_c.jpg)
The UK’s referendum decision to leave the EU in May 2016 undoubtedly sent shockwaves throughout Europe. European countries are still struggling to interpret what ‘Brexit’ will mean for them. Ireland,
![EMA to Work With Stakeholders to Improve Product Information For EU Medicines](http://www.biopharmabusiness.com/wp-content/uploads/2017/12/ECMedicines2-505x306_c.jpg)
The European Medicines Agency (EMA) has published an action plan to improve the product information (PI) for EU medicines, an information package for patients and healthcare professionals that accompanies every single medicine authorised in
![New Precision Medicine Centre of Excellence Will Improve Patient Treatment](http://www.biopharmabusiness.com/wp-content/uploads/2017/12/InvestNIMedicalDecember2017-505x306_c.jpg)
A £10 million Centre of Excellence in Precision Medicine has been launched by Invest Northern Ireland and Queen’s University Belfast. The Centre of Excellence in Precision Medicine will develop an
![Diaceutics Wins at Export Industry Awards](http://www.biopharmabusiness.com/wp-content/uploads/2017/12/DieticsDecember2017-505x306_c.jpg)
Diaceutics, the Irish data insights and solutions company helping patients receive potentially lifesaving medicine through better testing, won the Small & Emerging Exporter of the Year Award at the recent Export
![Brexit – Key Issues For the Pharmaceutical Industry](http://www.biopharmabusiness.com/wp-content/uploads/2017/12/McGeePharmaBrexitResized-505x306_c.jpg)
Brexit – the stark reality is that the UK’s EU membership and the application of all EU legislation in the UK ends automatically at midnight on 30th March 2019! Current understanding
![European Commission Diagnoses the State of Health in the EU](http://www.biopharmabusiness.com/wp-content/uploads/2017/12/ECHealth-505x306_c.jpg)
Only by rethinking our health systems can we ensure that they remain fit-for-purpose and provide patient-centred care. This is what the 28 Country Health Profiles recently published by the Commission,
![Anti-Pancreatic Cancer Drug In Research Focus](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/chemistbig-505x306_c.jpg)
Intriguing antitumor activity is found in a very promising class of natural compounds: cyclic depsipeptides, which have a challenging structure that makes their investigation difficult. Now, Chinese scientists have established
![Biopharma firm Regeneron to create 300 jobs in Limerick](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/Limerick-505x306_c.jpg)
US biopharma company Regeneron Pharmaceuticals is to create 300 new jobs in Ireland as part of a new $100 million investment. The company has announced a further expansion of its
![Brexit: Implications for the Pharma Industry in Ireland](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/o-BREXIT-facebook-505x306_c.jpg)
The UK’s referendum decision to leave the EU in May 2016 undoubtedly sent shockwaves throughout Europe. European countries are still struggling to interpret what ‘Brexit’ will mean for them. Ireland,
![FDA collaboration uses Organs-on-Chips to improve drug development](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/shutterstock_607562534org-505x306_c.jpg)
CN Bio Innovations Limited has announced today that it has entered into a Research Collaboration Agreement with the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research
![Ireland and the Life Science Industry – 2017](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/Ireland-and-the-life-Science-505x306_c.jpg)
The Life Science Industry The manufacturing industry in Ireland is now enjoying a renewed period of growth on the back of increased consumer demand in both Irish and overseas markets. This
![Tarloxitinib puts tumour-seeking tail on anti-EGFR drug to target lung cancer](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/tarloxitinib-505x306_c.jpg)
EGFR is a common genetic target in lung cancer, but not all EGFR mutations are created equal. Patients with a type of EGFR anomaly called an “EGFR exon 20 insertion”
![Anticoagulant drugs appear to reduce the risk of stroke in patients with AF](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/shutterstock_364107608Blood-thinning-drugs-505x306_c.jpg)
Blood-thinning drugs not only reduce the risk of stroke in patients with atrial fibrillation (AF) but are also associated with a significant reduction in the risk of dementia, according to
![Ketamine may help treat migraine pain unresponsive to other therapies](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/Ketamine-505x306_c.jpg)
Ketamine, a medication commonly used for pain relief and increasingly used for depression, may help alleviate migraine pain in patients who have not been helped by other treatments. The study
![Spotlight on Trends for API Warning Letters from October 2015 – June 2017](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/spotlight-505x306_c.jpg)
API Warning Letters Each spring, the FDA publishes data on its website related to Form 483 inspection observations and warning letters issued by the Centre for Drug Evaluation and Research (CDER) during
![PHE launches campaign to reign in use of antibiotics](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/pills_red_blue-505x306_c.jpg)
Public Health England has launched a major new campaign designed to further reign in inappropriate use of antibiotics, as estimates show that around 5,000 people in England alone die every
![FDA approves Bydureon BCise for patients with type-2 diabetes](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/Diabetes-type-2-200x157_c.jpg)
The FDA has approved Bydureon BCise for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines.
![New project to bring world-class medicines ‘smart’ packaging capability to the UK](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/medicinesss-200x157_c.jpg)
The Centre for Process Innovation (CPI), the UK’s technology innovation provider for process manufacturing, announced it has begun the first
![Scientists find where HIV ‘hides’ to evade detection by the immune system](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/medres-200x157_c.jpg)
In a decades-long game of hide and seek, scientists from Sydney’s Westmead Institute for Medical Research have confirmed for the
![Lilly signs up to cancer vaccines with CureVac deal](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/lilly-200x157_c.jpg)
Eli Lilly has signed up CureVac to develop cancer vaccines based on its mRNA technology, in a deal that could
![US approves second CAR-T therapy](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/cell-200x157_c.jpg)
Gilead’s Yescarta – recently acquired through its purchase of Kite Pharma -has become the second gene therapy to be approved
![Cork-based AventaMed eyes FDA approval after raising €1.8m](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/ppp-200x157_c.jpg)
AventaMed, a Cork-based medtech firm focused on simplifying surgical procedures, has secured a €1.8 million investment to enable the company
![More than 70 medtech companies to vie for investment](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/12334-200x157_c.jpg)
More than 70 Irish medical technology companies will seek investment from 300 international blue-chip company buyers from 42 countries on
![Agreement formed to develop and commercialise infectious diseases programme](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/Hand-shake-200x157_c.gif)
Visterra and Vir Biotechnology have entered into a research collaboration, exclusive licence and option agreement for the development and commercialisation
![Plasticell and GSK collaborate to produce hematopoietic cells](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/F_58165-200x157_c.jpg)
Plasticell, a biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK
![Mutabilis selected to join ENABLE consortium aimed at fighting antibiotic resistance](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/Antibiotic-resistance-200x157_c.gif)
A specialist in therapeutic approaches to treat resistant bacterial infections, Mutabilis has been selected to join the European consortium ENABLE
![Janssen announces FDA approval of Stelara for plaque psoriasis](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/shutterstock_526083928PS-200x157_c.jpg)
The FDA has approved an expanded indication for Stelara for the treatment of adolescents with moderate plaque psoriasis. Janssen Biotech,
![Titan gets under the skin of Parkinson’s with first patient administered with ropinirole implant](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/Parkinsons-200x157_c.gif)
Titan Pharmaceuticals has announced that the first patient has been treated in a Phase I/II trial of its ropinirole subdermal
![Development of new respiratory syncytial virus vaccine](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/F_58103-200x157_c.jpg)
SGS announced it has entered into collaboration with Bavarian Nordic A/S, an international biotechnology company specialising in vaccines, to develop
![CEL-SCI receives new European patent for investigational immunotherapy](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/Patent-200x157_c.gif)
The European Patent Office has issued a new patent to biotechnology company, CEL-SCI, for its lead investigational immunotherapy, which is
![Industrial robot market booming](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/robot-200x157_c.jpg)
The industrial robotics market is expected to be worth $71.7 billion by 2023, according to new research. The rapid growth
![Myeloma UK trial to test novel myeloma treatment approach](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/investigate-200x157_c.jpg)
Myeloma UK has launched a nationwide trial aiming to assess the effectiveness of a novel treatment combination that includes Darzalex
![FDA Gives Positive Review Of Aerie’s Experimental Glaucoma Drug](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/eyebig-200x157_c.jpg)
A study by the U.S. Food and Drug Administration has backed up Aerie Pharmaceutical’s evidence that its experimental drug is
![Team develop device to improve dialysis treatment](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/Dialysis-200x157_c.jpg)
A team of researchers from Imperial College London have used machine learning to develop a device that could potentially improve
![Gel Developed To Fight Rheumatoid Arthritis](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/hydrogels-200x157_c.jpg)
IBS scientists at the Center for Self-Assembly and Complexity, within the Institute for Basic Science (IBS), invented a hydrogel to
![Busting biotech wide open: BiOspace lab now open in Manchester](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/BiOspace-200x157_c.gif)
The first open-access biotech laboratory has opened in Manchester, affording early-stage biotech and medtech companies, as well as entrepreneurial individual
![Mental health patients to receive better care with connected technologies](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/World-Mental-Health-200x157_c.jpg)
Ahead of World Mental Health Day, a new project that uses connected technologies has been developed by the NHS to
![Synthetic biologists can now create novel vector constructs](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/F_57851-200x157_c.jpg)
Double Helix Technologies (Doulix) announced it will collaborate with Agilent Technologies to promote Agilent’s SureVector next-generation cloning kits through Doulix’s web
![Researchers Help Develop New Antifungal Drug](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/PP-laboratory-research-200x157_c.jpg)
University of Liverpool researchers, working with F2G Limited (Eccles, Manchester), have developed a new antifungal drug to help in the
![Tjoapack invests in bottle packing capabilities](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/F_57785-200x157_c.jpg)
Tjoapack, a Dutch contract packaging organisation (CPO), has added an additional bottling line to its facility in Etten-Leur, the Netherlands,
![Most approved oncology drugs do not offer better survival rate or quality of life, say researchers](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/Research-200x157_c.gif)
A retrospective cohort study, published in the British Medical Journal, has found no conclusive evidence that most oncology treatments approved
![Alcohol aversion drug Disulfiram may combat chemotherapy resistance](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/Lung-cancer-cell-200x157_c.jpg)
Scientists have had positive results from a laboratory-based study using a well-known alcohol aversion drug disulfiram, to combat chemotherapy resistance
![Researchers seek 500 NHS patients to test new universal flu jab](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/Flu-jab-200x157_c.gif)
The BBC has reported that researchers from the University of Oxford’s Jenner Institute are seeking 500 NHS patients to test
![Successor to PD-1 inhibitors the focus of cancer immunotherapy](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/F_57714-200x157_c.jpg)
The cancer immunotherapy pipeline, displays a high level of first-in-class innovation with novel developments focusing heavily on producing the next
![Synthetic mini-protein binders may provide a new class of drugs](http://www.biopharmabusiness.com/wp-content/uploads/2017/10/Protein-200x157_c.gif)
Scientists at the University of Washington (UW) have designed mini-protein binders on a computer platform, which are not naturally occurring